Insoluble drugs, referring to drugs with poor water solubility, can lead to difficulties in absorption and transport of drugs in vivo, and low bioavailability. About 40% of the newly discovered natural active substances and nearly 60% of the chemically synthesized drugs are insoluble drugs. Their solubility (in water) is poor, and it is difficult to achieve satisfactory clinical efficacy. They have not been further successfully developed into new drugs. Therefore, using physical and chemical means to improve the solubility of insoluble drugs, so as to improve the clinical efficacy, is one of the important directions of new drug research and development.Betadex sulfobutyl ether sodium,is beta - cyclodextrin derivatives, because it has good water solubility and biocompatibility, can obviously increase the drug solubility and bioavailability, at the same time with similar biological activity and low renal toxicity of heparin, as a new injection drug delivery carrier, has become one of the hot spot in new drug research and development at home and abroad.
The preparation of inclusion complex of Betadex sulfobutyl ether sodium with insoluble drugs such as docetaxel, amiodarone and calyx A was studied. The freeze-dried inclusion complex for injection was obtained. It lays a theoretical foundation for the development and clinical application of Betadex sulfobutyl ether sodium as an injection drug carrier.
The solubility of docetaxel and Betadex sulfobutyl ether sodium increased by about 800 times, that of blue calyx A and Betadex sulfobutyl ether sodium increased by 76 times, and that of amiodarone and Betadex sulfobutyl ether sodium increased by 195 times. All these provide a basis for the development of new dosage forms for injection.
Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. cooperates with Shandong University to set up a research and development laboratory, which is dedicated to the research of beta-cyclodextrin and its derivatives, such as Betadex sulfobutyl ether sodium and Hydroxypropyl beta-cyclodextrin, to provide technical support for inclusion complexes of beta-cyclodextrin and its derivatives, and to provide inclusion solution for customers.